Joel M. Vaz

Joel M. Vaz

Auto-generated profile, based on publicly available information

Joel M. Vaz

Human Biology Division, Fred Hutchinson Cancer Center

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
IGIlaria Gritti
Ilaria Gritti
JWJinkai Wan
Jinkai Wan
VWVajira Weeresekara
Vajira Weeresekara
JVJoel M. Vaz
Joel M. Vaz
GTGiuseppe Tarantino
Giuseppe Tarantino
NBNabeel Bardeesy
Nabeel Bardeesy
Fibrolamellar carcinoma (FLC) is a liver cancer of adolescents and young adults characterized by fusions of the genes encoding the protein kinase A catalytic subunit, PRKACA, and heat shock protein, DNAJB1. The chimeric DNAJB1-PRKACA protein has increased kinase activity and is essential for FLC xenograft growth. Here, we explore the critical oncogenic pathways controlled by DNAJB1-PRKACA using patient-derived FLC models, engineered systems, and patient samples. We show that a core function of DNAJB1-PRKACA is the phosphorylation and inactivation of salt-inducible kinases (SIKs). This leads to deregulation of the CRTC2 transcriptional coactivator and p300 acetyltransferase, resulting in transcriptional reprogramming and increased global histone acetylation, driving malignant growth. Our studies establish a central oncogenic mechanism of DNAJB1-PRKACA and suggest the potential of targeting CRTC2/p300 in FLC. Notably, these findings link this rare cancer’s signature fusion oncoprotein to more common cancer gene alterations involving STK11 and GNAS, which also function via SIK suppression. Significance: This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the SIK stimulates CRTC2-p300-mediated transcription to drive tumor growth. The findings illuminate pathogenic mechanisms and inform therapeutic development.

10 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MCMarina Chan
Marina Chan
SZSongli Zhu
Songli Zhu
ZRZachary R. Russell
Zachary R. Russell
SASonali Arora
Sonali Arora
AAAleena K. S. Arakaki
Aleena K. S. Arakaki
TSTJ Singh
TJ Singh
Ependymomas (EPN) are rare central nervous system tumors that account for approximately 10% of intracranial tumors in children and 4% in adults. Despite their clinical and molecular heterogeneity, spanning supratentorial, posterior fossa, and spinal subtypes, treatment remains limited to surgery and radiotherapy, with chemotherapy offering minimal benefit. Here, we performed transcriptomic analysis of 370 human ependymoma samples and identified two distinct molecular subgroups: EPN-E1 and EPN-E2. The EPN-E1 cluster is enriched for supratentorial tumors harboring ZFTA-RELA fusions (ZFTA-RELA fus ), which occur in over 70% of cases and are associated with poor prognosis. To identify targeted therapies for this aggressive subtype, we validated a ZFTA-RELA fus mouse model that recapitulates the human EPN-E1 transcriptome and used it for target discovery. Through Kinome Regularization, a machine learning-driven polypharmacology approach, we identified MERTK as a critical regulator of tumor cell viability. Genetic depletion or pharmacologic inhibition of Mertk reduced cell growth ex vivo, and treatment with a clinical-grade MERTK inhibitor significantly suppressed tumor proliferation in vivo. Both human EPN-E1 tumors and ZFTA-RELA fus mouse tumors exhibited elevated expression of MERTK and its ligand GAS6, and MERTK inhibition led to suppression of pro-survival signaling pathways including MEK/ERK (Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase) and PI3K/AKT (Phosphoinositide 3-Kinase/Protein Kinase B). Notably, over 80% of genes upregulated in ZFTA-RELA fus tumors were downregulated following MERTK inhibition, indicating a strong dependency on this pathway for tumor maintenance. These findings define a signaling vulnerability in ZFTA-RELA-driven ependymomas and support the clinical development of MERTK-targeted therapies for patients with the high-risk EPN-E1 subtype.

7 February 2025
Verified
Other
Open access
IGIlaria Gritti
Ilaria Gritti
JWJinkai Wan
Jinkai Wan
VWVajira Weeresekara
Vajira Weeresekara
JVJoel M. Vaz
Joel M. Vaz
GTGiuseppe Tarantino
Giuseppe Tarantino
NBNabeel Bardeesy
Nabeel Bardeesy
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set

7 February 2025
Verified
Other
Open access
PDF file
IGIlaria Gritti
Ilaria Gritti
JWJinkai Wan
Jinkai Wan
VWVajira Weeresekara
Vajira Weeresekara
JVJoel M. Vaz
Joel M. Vaz
GTGiuseppe Tarantino
Giuseppe Tarantino
NBNabeel Bardeesy
Nabeel Bardeesy
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo. Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.

21 February 2025
Verified
Other
Open access
IGIlaria Gritti
Ilaria Gritti
JWJinkai Wan
Jinkai Wan
VWVajira Weeresekara
Vajira Weeresekara
JVJoel M. Vaz
Joel M. Vaz
GTGiuseppe Tarantino
Giuseppe Tarantino
NBNabeel Bardeesy
Nabeel Bardeesy
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set